GT
EWTX icon

Glenmede Trust’s Edgewise Therapeutics EWTX Stock Holding History

Glenmede Trust’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$995K Buy
24,484
+5,260
+27% +$181K ﹤0.01% 764
2026
Q1 		$606K Buy
+19,224
New +$554K ﹤0.01% 895
2025
Q1 		$480K Sell
21,809
-110
-0.5% -$2.89K ﹤0.01% 923
2024
Q4 		$585K Buy
21,919
+3,834
+21% +$122K ﹤0.01% 874
2024
Q3 		$483K Buy
+18,085
New +$360K ﹤0.01% 943

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Glenmede Trust's EWTX Position: Q2 2026 in Review

Glenmede Trust increased its Edgewise Therapeutics (EWTX) stake by 27% in Q2 2026, buying an estimated $181K and bringing the position to 24,484 shares worth $995K. The position accounts for ﹤0.01% of the portfolio, ranked #764.

Glenmede Trust first reported a position in EWTX in Q3 2024 and has held it in 5 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Glenmede Trust held 24,484 shares of Edgewise Therapeutics worth $995K as of Q2 2026.
  • Glenmede Trust bought 5,260 Edgewise Therapeutics shares in Q2 2026, an estimated $181K.
  • Edgewise Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #764 holding.
  • Glenmede Trust first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.